Provides cancer and cardiovascular screenings to law enforcement officers; establishes fund; appropriates $20 million.
Impact
A significant feature of the bill is the establishment of the 'SHBP Law Enforcement Cancer and Cardiovascular Disease Screenings Fund', which will be replenished through a $10 surcharge on motor vehicle summonses. The bill appropriates $20 million from the State General Fund to support the screenings and fund reimbursements. This financial support ensures that public employers can manage the costs associated with these mandated screenings. The implementation of this bill will affect existing healthcare policies within law enforcement agencies, ensuring that health benefits include these crucial screenings without additional costs for officers.
Summary
Senate Bill S3967, introduced in New Jersey, aims to provide cancer and cardiovascular disease screenings to law enforcement officers. The bill mandates routine screenings every three years for various types of cancers, including colon, lung, and prostate cancers, commencing not less than three years after a law enforcement officer's employment begins. This is intended to improve the overall health and well-being of officers who often face higher risks for certain health conditions due to the nature of their work. Additionally, the bill allows for reimbursement of health care costs related to these screenings, further supporting officers' access to necessary medical examinations.
Contention
The introduction of S3967 highlights a broader conversation around the health and safety of law enforcement personnel. While the bill is largely viewed as a positive advance for officer health, there may be discussions regarding the long-term sustainability of funding mechanisms and the implications of additional financial burdens on municipalities. Opponents might argue about the potential for increased costs associated with implementing these requirements, especially in smaller jurisdictions that already struggle to support their officers adequately. How the specified funding will be maintained and if it will require future legislative adjustments presents potential points of contention.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.